MedTrace Logo

The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients

NCT01854814 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 238

Last updated 2022-07-11

No results posted yet for this study

Summary

The study is to evaluate the effect of Mycophenolate Mofetil compared with losartan alone on time to doubling of serum creatinine or the onset of end stage renal disease in patients with advanced IgA nephropathy who are treated with the maximal tolerated daily dose of losartan.The study will also assess the effects of MMF compared with losartan alone on the changes of urine albumin excretion and the changes in estimated glomerular filtration rate.

Conditions

Interventions

DRUG

Mycophenolate mofetil

Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan

DRUG

Losartan

Maximum tolerated labeled dose of Losartan

Sponsors & Collaborators

  • Fan Fan Hou

    lead OTHER

Principal Investigators

  • Fan Fan Hou, M.D., PhD · Division of nephrology, Nanfang Hospital Southern Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2022-02-28
Completion
2022-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01854814 on ClinicalTrials.gov